Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Baxter
Medtronic
Mallinckrodt
Express Scripts

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR MARIBAVIR


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Maribavir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002373 ↗ The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients Completed Glaxo Wellcome Phase 1 1969-12-31 To evaluate the safety and tolerability of multiple escalating doses of 1263W94 administered orally for 28 days in HIV infected patients with asymptomatic CMV shedding. To obtain preliminary evidence of the in vivo anti CMV activity of different doses of 1263W94 in humans based on quantitative reduction of CMV load in semen and if possible in other biological fluids and to explore the dose response relationship in the anti-CMV activity of 1263W94.
NCT00223925 ↗ Maribavir for Prevention of CMV After Stem Cell Transplants Completed Shire Phase 2 2004-10-28 Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. Maribavir is a new oral anti-CMV drug with a novel mechanism of action compared to currently available anti-CMV drugs. This study will test the safety and anti-CMV activity of different doses of maribavir when given as CMV prophylaxis following stem cell transplants.
NCT00411645 ↗ Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients Completed Shire Phase 3 2006-12-13 The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Maribavir

Condition Name

Condition Name for Maribavir
Intervention Trials
Cytomegalovirus (CMV) 6
Cytomegalovirus Infections 5
Healthy Volunteers 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Maribavir
Intervention Trials
Infections 6
Cytomegalovirus Infections 6
Communicable Diseases 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Maribavir

Trials by Country

Trials by Country for Maribavir
Location Trials
United States 135
France 17
Belgium 13
United Kingdom 12
Canada 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Maribavir
Location Trials
New York 7
California 7
Florida 6
Washington 6
Texas 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Maribavir

Clinical Trial Phase

Clinical Trial Phase for Maribavir
Clinical Trial Phase Trials
Phase 3 6
Phase 2 2
Phase 1 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Maribavir
Clinical Trial Phase Trials
Completed 8
Not yet recruiting 4
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Maribavir

Sponsor Name

Sponsor Name for Maribavir
Sponsor Trials
Shire 9
Takeda 3
Takeda Development Center Americas, Inc. 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Maribavir
Sponsor Trials
Industry 16
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Baxter
Dow
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.